Table 1.
Clinicopathologic Characteristics of Patients in Each Study Arm
| Variables | Adjuvant Radiotherapy Arma | Salvage Radiotherapy Armb |
|---|---|---|
| No. of Patients | 150 | 115 |
| Age at RP, y | ||
| Median (range) | 64 (46‐76) | 63 (48‐75) |
| IQR (Q1‐Q3) | 59‐69 | 58‐67 |
| Race | ||
| White (non‐Hispanic) | 126 (84%) | 95 (82.6%) |
| White (Hispanic) | 9 (6%) | 8 (7%) |
| Black/African | 11 (7.3%) | 12 (10.4%) |
| Asian | 3 (2%) | ‐ |
| Unknown | 1 (0.7%) | ‐ |
| Preoperative PSA, ng/mL | ||
| Median (range) | 6.3 (0.9‐40.5) | 6.7 (0.8‐55.5) |
| IQR (Q1‐Q3) | 4.9‐10 | 4.7‐9.4 |
| <10 | 110 (73.3%) | 86 (74.8%) |
| 10‐20 | 30 (20%) | 20 (17.4%) |
| >20 | 8 (5.3%) | 5 (4.3%) |
| PSA at time of enrollment, ng/mL | ||
| Median (range) | 0.2 (0.0‐4.0) | |
| IQR (Q1‐Q3) | 0.1‐0.3 | |
| Extraprostatic extension, no. (%) | ||
| Present | 99 (66%) | 45 (39.1%) |
| Seminal vesicle invasion, no. (%) | ||
| Present | 22 (14.7%) | 14 (12.2%) |
| Surgical margin, no. (%) | ||
| Positive | 75 (50%) | 56 (48.7%) |
| Lymph node invasion, no. (%) | ||
| Positive | 2 (1.3%) | 2 (1.7%) |
| Pathologic Gleason score, no. (%) | ||
| 6 | 2 (1.3%) | 9 (7.8%) |
| 7 | ||
| 3+4 | 78 (52%) | 49 (42.6%) |
| 4+3 | 41 (27.3%) | 36 (31.3%) |
| 8 | 17 (11.3%) | 9 (7.8%) |
| 9 | 12 (8%) | 12 (10.4%) |
| Pathological T classification, no. (%) | ||
| T2 | 40 (26.7%) | 53 (46.1%) |
| T3a | 78 (52%) | 35 (30.4%) |
| T3b | 22 (14.7%) | 14 (12.2%) |
| Unknown | 10 (6.7%) | 13 (11.3%) |
| Decipher risk probability at 5 y after RP | ||
| Median (range) | 6.2% (0.5%‐44.2%) | 6.5% (0.5%‐62.8%) |
| IQR (Q1‐Q3) | 2.4%‐11.2% | 2.7%‐14.4% |
| Low | 69 (46%) | 38 (33%) |
| Intermediate | 33 (22%) | 29 (25.2%) |
| High | 48 (32%) | 48 (41.7%) |
Abbreviations: IQR, interquartile range; PSA, prostate‐specific antigen; Q, quartile; RP, radical prostatectomy.
a
In the adjuvant radiotherapy arm, unknown preoperative PSA, extraprostatic extension, seminal vesicle invasion, and lymph node invasion status for 2, 4, 9, and 21 patients, respectively.
b
In salvage radiotherapy arm, unknown preoperative PSA, extraprostatic extension, seminal vesicle invasion, and lymph node invasion status for 4, 10, 8, and 20 patients, respectively.